Literature DB >> 11484222

Modeling of the metallo-beta-lactamase from B. fragilis: structural and dynamic effects of inhibitor binding.

F R Salsbury1, M F Crowley, C L Brooks.   

Abstract

The structure and dynamics of an inhibitor-bound complex of the metallo-beta-lactamase from Bacteroides fragilis are studied by using molecular dynamics. A search of the conformational space was performed to obtain three distinct models of the complex, which were then subjected to solvated molecular dynamics. A solvated molecular dynamics study of the apo protein was performed to serve as a baseline for comparison with the bound simulations. We find loop conformation changes due to binding as well as a decrease in flexibility of the protein as a whole and especially in the major loop of the beta-lactamase. We report the structural and dynamical features of the inhibitor-bound and apo models, as well as experimentally measurable quantities, which should be capable of distinguishing the two binding modes we have determined. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11484222     DOI: 10.1002/prot.1110

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  11 in total

1.  Role of a solvent-exposed tryptophan in the recognition and binding of antibiotic substrates for a metallo-beta-lactamase.

Authors:  James J A Huntley; Walter Fast; Stephen J Benkovic; Peter E Wright; H Jane Dyson
Journal:  Protein Sci       Date:  2003-07       Impact factor: 6.725

2.  Impact of remote mutations on metallo-beta-lactamase substrate specificity: implications for the evolution of antibiotic resistance.

Authors:  Peter Oelschlaeger; Stephen L Mayo; Juergen Pleiss
Journal:  Protein Sci       Date:  2005-03       Impact factor: 6.725

Review 3.  Molecular dynamics simulations of protein dynamics and their relevance to drug discovery.

Authors:  Freddie R Salsbury
Journal:  Curr Opin Pharmacol       Date:  2010-12       Impact factor: 5.547

4.  Molecular dynamic simulations of the metallo-beta-lactamase from Bacteroides fragilis in the presence and absence of a tight-binding inhibitor.

Authors:  Freddie R Salsbury; Michael W Crowder; Stephen F Kingsmore; James J A Huntley
Journal:  J Mol Model       Date:  2008-11-28       Impact factor: 1.810

5.  Non-specificity and synergy at the binding site of the carboplatin-induced DNA adduct via molecular dynamics simulations of the MutSα-DNA recognition complex.

Authors:  Lacramioara Negureanu; Freddie R Salsbury
Journal:  J Biomol Struct Dyn       Date:  2013-06-25

6.  Bulgecin A: a novel inhibitor of binuclear metallo-beta-lactamases.

Authors:  Alan M Simm; E Joel Loveridge; John Crosby; Matthew B Avison; Timothy R Walsh; Peter M Bennett
Journal:  Biochem J       Date:  2005-05-01       Impact factor: 3.857

7.  Site-selective binding of Zn(II) to metallo-beta-lactamase L1 from Stenotrophomonas maltophilia.

Authors:  Alison Costello; Gopalraj Periyannan; Ke-Wu Yang; Michael W Crowder; David L Tierney
Journal:  J Biol Inorg Chem       Date:  2006-02-18       Impact factor: 3.358

8.  Destabilization of the MutSα's protein-protein interface due to binding to the DNA adduct induced by anticancer agent carboplatin via molecular dynamics simulations.

Authors:  Lacramioara Negureanu; Freddie R Salsbury
Journal:  J Mol Model       Date:  2013-09-24       Impact factor: 1.810

9.  Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.

Authors:  Dmitriy Minond; S Adrian Saldanha; Prem Subramaniam; Michael Spaargaren; Timothy Spicer; Joseph R Fotsing; Timo Weide; Valery V Fokin; K Barry Sharpless; Moreno Galleni; Carine Bebrone; Patricia Lassaux; Peter Hodder
Journal:  Bioorg Med Chem       Date:  2009-06-22       Impact factor: 3.641

10.  Probing substrate binding to metallo-beta-lactamase L1 from Stenotrophomonas maltophilia by using site-directed mutagenesis.

Authors:  Anne L Carenbauer; James D Garrity; Gopal Periyannan; Robert B Yates; Michael W Crowder
Journal:  BMC Biochem       Date:  2002-02-13       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.